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Amyloid fibrils were isolated from the kidney of a patient with Finnish hereditary amyloidosis. After solubilization of the fibrils in guanidine-HCI, 
fractionation by gel filtration, and purification by reverse-phase high-performance liquid chromatography, a homogeneous amyloid protein with 
an apparent M, of 9000 was obtained. The protein was subjected to enzymatic digestion by trypsin and endoproteinase Lys-C. The amino acid 
sequences were determined for 6 of the released peptides and they were all found to be identical to the reported, deduced primary structure of 
human plasma gelsoline in the region of amino acids 235-269. The results show that the amyloid tibril protein in Finnish hereditary ~yloidosis 
represents anew type of amyloid protein that shows amino acid sequence homology with gelsoline, an actin-m~ulating protein. 
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1. INTRODUCTION 
Familial amyloid polyneuropathy (FAP) syndromes 
are autosomal dominant disorders characterized by ex- 
tracellular deposits of fibrillar protein with crossed ,& 
pleated sheet conformation and a clinical syndrome of 
pol~europathy [l]. The Finnish type of hereditary 
amyloidosis (FAP type IV) is characterized by a 
systemic disease with a distinct clinical picture involv- 
ing progressive cranial neuropathy, cornea1 lattice 
dystrophy and distal sensorimotor neuropathy 121. 
More than 300 cases have been recorded in the Finnish 
population [3]. In contrast to FAP type I and FAP type 
II syndromes which have been shown to be caused by 
specific variant transthyretin molecules that deposit in 
tissues as amyloid [4-lo], the biochemical nature of the 
amyloid fibril protein in FAP type IV has remained 
unresolved 13,111. Here we report the isolation and 
purification of kidney amyloid in Finnish hereditary 
amyloidosis and show amino acid sequence homology 
of the major M, 9000 amyloid protein with the inner 
portion of human plasma gelsoline. 
2. MATERIALS AND METHODS 
2. I. Materials 
Amyloid fibrils were isolated from the kidney of a 71-year-old man 
with Finnish hereditary amyloidosis. The amyloid tissue sample and 
control non-amyloid renal tissue sample, were obtained at autopsy 
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and kept at -70°C until processed. Congo-red staining and 
microscopy under polarized light revealed amyloid in the glomerular 
capillaries and to a slighter extent in larger blood vessels and in the 
interstitium in the case of amyloidosis, whereas the control renal 
tissue sample was negative with respect to amyloid. 
Sephadex G-100 was from Pharmacia (Uppsala, Sweden), trypsin- 
TPCK was from Sigma Chemical Co. (St. Louis, MO, USA), and en- 
doproteinase Lys-C Sequence Grade from Boehringer Mannheim 
(M~nheim, FRG). The chemicals as well as other materials needed 
for sequencing and high-performance liquid chromatography 
(HPLC) were of Protein Sequencing Grade and were obtained from 
Applied Biosystems Ltd. (Warrington, UK). Polyacrylamide gel elec- 
trophoresis was performed in 15-17% gels, as described [12]. 
2.2. isolation and pur@cation of amyloid proteins 
Using a modifi~tion of the original procedure of Pras et al. 1131, 
61.7 g of amyloid renal tissue was homogenized in 0.9% NaCl, 
200 ml, followed by centrifugation at 12000 rpm for 30 min. The 
supernatant was discarded and the pellet then washed, repeating the 
procedure twice with 0.9% NaCl, twice with 0.1 M phosphate- 
buffered saline, and 6 times with 0.9Yo NaCl. The final sediment was 
homogenized in distilled HzO, 100 ml each time, 15 times. The super- 
natants were lyop~lized and subjected to Congo-red staining. The 5 
last washings were all positive. Supernatant 12, with a high content 
of amyloid fibrils, was chosen for further purification. The lyophiliz- 
ed sample was denatured in 6 M guanidine-HCl buffered to pH 8.5 
with 0.5 M Tris-HCl containing 0.002 M EDTA and 20 mM 
dithiothreitol. The sample was incubated at 37°C for 3 h and kept at 
room temperature overnight. After centrifugation, the supernatant, 
containing 69 mg protein, was chromato~aphed on a Sephadex 
G-100 column (1.5 x 98 cm) using 5 M guanidine-HCl with 1 M 
acetic acid as eluent. The pooled fraction of the retarded peak was 
purified on reverse-phase HPLC (Beckman, System Gold, Program- 
mable Solvent Module 126, SP 8450, UV/VIS detector, Spectra 
Physics Merck Hitachi D-2500 Chromato-Integration) using a Vydac 
C~S column and a lo-80% acetonitrile gradient in 0.1% 
trifluoroacetic acid. 
2.3, Peptide fragmentation and separation on reverse-phase HPLC 
The amyloid protein was alkylated and desalted and repurified on 
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Fig.1. Gel filtration on Sephadex G-100 of extracted renal amyloid. 
The elution was performed with 5 M guanidine-HCI in 1 M acetic 
acid. The retarded peak containing the monomeric amyloid proteins 
was pooled as indicated. 
HPLC. Tryptic digestion was carried out in 1% ammonium bicar- 
bonate; incubation with 3070 (w/w) of trypsin for 2 h at 37°C was 
followed by another addition (3qo) of the protease and continued in- 
cubation overnight at 37°C. The released peptides were separated by 
reverse-phase HPLC using a Vydac Crs column equilibrated with 
0.1% trifluoroacetic acid in water, with a linear gradient of 
acetonitrile (O-60%) in 60 min. Digestion with endoproteinase Lys-C 
was carried out in 25 mM Tris-HCl buffer, pH 8.5; incubation with 
3% (w/w) of enzyme for 2 h at 37°C was followed by another addi- 
tion of the protease (3%) and continued incubation overnight at 
20°C. The released peptides were separated by HPLC as described 
above. 
2.4. Amino acid sequence analysis 
The sequence analysis was performed by automated Edman 
degradation using a modified Applied Biosystems 477A/120A on-line 
pulsed liquid phase/gas equencer in the gas phase mode. The NBRF 
Swiss-PROT sequence database 11.0, June 1989, was used for com- 
puter search of sequence homologies. 
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Fig.2. Polyacrylamide gel electrophoresis of the amyloid fraction 
(lane ‘b’). Lane ‘a’ shows molecular mass markers (IX x lo-‘). 
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Fig.3. Reverse-phase HPLC of the isolated amyloid protein. 
Column, Vydac Crs; solvent system, a linear gradient of acetonitrile 
(O-80%) in 0.1% trifluoroacetic acid. 
3. RESULTS 
Fig.1 shows the gel filtration curve of the extracted 
renal amyloid. Gel electrophoresis of the retarded peak 
revealed two bands in the low molecular weight region 
(fig.2). These bands were absent in the gel elec- 
trophoretic runs of corresponding fractions of extracts 
from normal kidney. The amyloid protein fraction was 
then purified on reverse-phase HPLC and the major 
peak isolated (fig.3). The apparent molecular mass of 
the peptide was 9 kDa as judged from gel elec- 
trophoresis. Direct sequence analysis of the amino- 
terminus of the amyloid protein was not feasible. After 
alkylation, the protein was digested by trypsin and en- 
doproteinase Lys-C and the released peptides sequenc- 
ed. All the sequences determined were identical with the 
reported primary sequence of human plasma gelsoline 
in the region of amino acids 235-269 as shown in fig.4. 
4. DISCUSSION 
Several types of amyloid fibril proteins have been 
identified in the systemic forms of amyloidosis [14]. 
Under these conditions the amyloid proteins are com- 
posed of whole or fragmented plasma proteins. In 
primary and myeloma-associated amyloidosis, the 
amyloid protein is related to immunoglobulin light 
chains, in secondary amyloidosis to serum amyloid A 
protein, in haemodialysis-associated amyloidosis to 
,&-microglobulin, and in the familial polyneuropathic 
amyloidosis to transthyretin (prealbumin). Recent 
biochemical studies of the transthyretin amyloid pro- 
teins in various FAP syndromes have shown that they 
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Fig.4. Amino acid sequences of proteolytic peptides 1-6 of amyloid fibril protein. Peptides 1-3, 5 and 6 were obtained by trypsin digestion and 
peptide 4 by endoproteinase Lys-C digestion. The region shown of the deduced primary structure of human plasma gelsoline is from [16], and 
the numbers 227 and 255 refer to the amino acid positions starting from the signal peptide. 
are expressions of specific single amino acid alterations 
in the transth~etin molecules [S-10]. However, the 
biochemical nature of the amyloid fibril protein in the 
Finnish hereditary amyloidosis has remained unclear. 
The clinically different expression of the FAP syn- 
drome in the Finnish form has raised the possibility 
that the fibril protein in this syndrome may have a uni- 
que structure. The results of this study indicate that the 
amyloid protein in Finnish hereditary ~yloidosis 
represents a novel type of amyloid protein that shows 
amino acid homology with the inner portion of human 
gelsoline. 
Gelsoline (M -90000) is an actin-modulating pro- 
tein found in a variety of mammalian tissues [15-171. 
It binds actin monomers, nucleates actin filament 
growth, and severs actin filaments. Plasma gelsoline 
represents a slightly larger form (MI -93000) of 
gelsoline that is present in human plasma at a concen- 
tration of about 200 mg/l [IS]. Both forms of gelsoline 
are derived by alternative transcriptional initiation sites 
and message processing from a single gene [ 16,171. The 
function of circulating gelsoline has not been defined, 
but it may be essential for the clearance of actin 
filaments released into the bloodstream on extracellular 
space during tissue injury and cell senescence. The 
results of this study suggest hat plasma gelsoline may 
be involved in the pathogenesis of a neurometabolic 
disease, the Finnish FAP type IV. 
The Mr of the monomeric amyloid protein was of the 
order of 9000, thus representing a fragment of the 
putative plasma precursor, gelsoline. Whether the frag- 
ment contains a specific amino acid alteration with 
respect to the corresponding region of normal 
gelsoline, explaining a possible defect in the proteolytic 
processing of the molecule in Finnish FAP type IV, is 
not known at present. The amino acid sequences of all 
enzymatically derived peptides sequenced in this study 
were exactly homologous to the reported, deduced 
primary structure of human plasma gelsoline in the 
region of amino acids 235-269, leaving, however, gaps 
at positions 238, 239 and 253-257. 
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